+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergic Conjunctivitis - Pipeline Review, H2 2019

  • ID: 4901307
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 99 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Ajanta Pharma Ltd
  • Allakos Inc
  • Clevexel Pharma SAS
  • Eleusis Ltd
  • Marinomed Biotech AG
  • Ocular Therapeutix Inc
  • MORE
Allergic Conjunctivitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2019, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 9 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ajanta Pharma Ltd
  • Allakos Inc
  • Clevexel Pharma SAS
  • Eleusis Ltd
  • Marinomed Biotech AG
  • Ocular Therapeutix Inc
  • MORE
Introduction
Report Coverage
Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Ajanta Pharma Ltd
Aldeyra Therapeutics Inc
Allakos Inc
Allergan Plc
Clevexel Pharma SAS
Dhp Korea Ltd
Eleusis Ltd
iCo Therapeutics Inc
Marinomed Biotech AG
NeuBase Therapeutics Inc
Noveome Biotherapeutics Inc
Ocular Therapeutix Inc
OKYO Pharma Ltd
Portola Pharmaceuticals Inc
RAPT Therapeutics Inc
Re-Pharm Ltd
Stuart Therapeutics Inc
Sylentis SAU
Xencor Inc
Allergic Conjunctivitis - Drug Profiles
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Allergic Conjunctivitis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Allergic Conjunctivitis - Pipeline by Ajanta Pharma Ltd, H2 2019
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Allergic Conjunctivitis - Pipeline by Allakos Inc, H2 2019
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2019
Allergic Conjunctivitis - Dormant Projects, H2 2019
Allergic Conjunctivitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Allergic Conjunctivitis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Allergic Conjunctivitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ajanta Pharma Ltd
  • Aldeyra Therapeutics Inc
  • Allakos Inc
  • Allergan Plc
  • Clevexel Pharma SAS
  • Dhp Korea Ltd
  • Eleusis Ltd
  • iCo Therapeutics Inc
  • Marinomed Biotech AG
  • NeuBase Therapeutics Inc
  • Noveome Biotherapeutics Inc
  • Ocular Therapeutix Inc
  • OKYO Pharma Ltd
  • Portola Pharmaceuticals Inc
  • RAPT Therapeutics Inc
  • Re-Pharm Ltd
  • Stuart Therapeutics Inc
  • Sylentis SAU
  • Xencor Inc
Note: Product cover images may vary from those shown
Adroll
adroll